Early-Invasive Urothelial Bladder Carcinoma and Instillation Treatment of Non-muscle-Invasive Bladder Cancer

2019 ◽  
pp. 327-335
Author(s):  
Wolfgang Otto ◽  
Maximilian Burger ◽  
Johannes Breyer
Keyword(s):  
Bladder Cancer ◽  
Bladder Carcinoma ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
Urothelial Bladder Carcinoma ◽  
Urothelial Bladder ◽  
Muscle Invasive

Superior molecular pathology of urothelial bladder cancer using urinary cell-free DNA.

2021 ◽  
Vol 39 (6_suppl) ◽  
pp. 491-491
Author(s):  
Ruiyun Zhang ◽  
Feng Xie ◽  
Yue Zhang ◽  
Yiqiu Wang ◽  
Zhixin Zhao ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Molecular Pathology ◽  
Predictive Value ◽  
Invasive Bladder Cancer ◽  
Urothelial Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
Cell Free Dna ◽  
Free Dna ◽  
Urothelial Bladder ◽  
Muscle Invasive

491 Background: Both urinary and blood cell-free DNA (cfDNA) have been implicated in noninvasive detection and surveillance of urothelial bladder cancer (UBC). However, a direct comparison of their diagnostic performance in the real-world setting is lacking. Methods: 59 eligible cases with pathologically confirmed disease and accompanying tissue/urine pairs were prospectively enrolled and consented to Institutional Review Board-approved protocols. Baseline peripheral blood mononuclear cell (PBMC) and plasma specimens were collected during clinic visit. The 180-gene Predicine liquid biopsy assay was applied for ultra-deep targeted sequencing and somatic alteration identification in tumor tissue-based DNA (tDNA), urinary cfDNA (ucfDNA) and blood cfDNA (bcfDNA). Results: The 59 studied subjects constituted a natural UBC cohort of non-muscle invasive bladder cancer (NMIBC) and muscle invasive bladder cancer (MIBC), including 48 (81.4%) NMIBC and 42 (71.2%) male patients. Diverse quantitative metrics such as VAF (variant allele frequency) and TMB (tumor mutational burden) were invariably concordant between tDNA and ucfDNA, but not bcfDNA. The mutational landscape captured by tDNA or ucfDNA highly resembled each other and mirrored previously described genomic panorama of UBC, whereas a significant proportion of bcfDNA aberrations stemmed from clonal hematopoiesis. Using tDNA-informed variants as the ground truth, ucfDNA assays achieved a specificity of 99.3%, a sensitivity of 86.7%, a positive predictive value (PPV) of 67.2%, a negative predictive value (NPV) of 99.8%, and a diagnostic accuracy of 99.1%, which were generally lower in the case of bcfDNA analysis. Conclusions: Urine-based molecular pathology provides valid and complete genetic information about neoplastic lesions, and represents a faithful surrogate for genotyping and monitoring UBC.

scholarly journals SEOM Clinical Guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2016)

2016 ◽  
Vol 18 (12) ◽  
pp. 1197-1205 ◽  
Author(s):  
M. Lázaro ◽  
E. Gallardo ◽  
M. Doménech ◽  
Á. Pinto ◽  
A. González del Alba ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Performance Status ◽  
Molecular Classification ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
Pathologic Evaluation ◽  
Function Impairment ◽  
Risk Patients ◽  
Urothelial Bladder ◽  
Muscle Invasive

Abstract The goal of this article is to provide recommendations for the diagnosis and treatment of muscle-invasive and metastatic bladder cancer. The diagnosis of muscle-invasive bladder cancer is made by pathologic evaluation after transurethral resection. Recently, a molecular classification has been proposed. Staging of muscle-invasive bladder cancer must be done by computed tomography scans of the chest, abdomen and pelvis and classified on the basis of UICC system. Radical cystectomy and lymph node dissection are the treatment of choice. In muscle-invasive bladder cancer, neoadjuvant chemotherapy should be recommended in patients with good performance status and no renal function impairment. Although there is insufficient evidence for use of adjuvant chemotherapy, its use must be considered when neoadjuvant therapy had not been administered in high-risk patients. Multimodality bladder-preserving treatment in localized disease is an alternative in selected and compliant patients for whom cystectomy is not considered for clinical or personal reasons. In metastatic disease, the first-line treatment for patients must be based on cisplatin-containing combination. Vinflunine is the only drug approved for use in second line in Europe. Recently, immunotherapy treatment has demonstrated activity in this setting.

scholarly journals Role of TROP2, Cyclin D1 and FOXP3 in Bladder Carcinoma in Egyptian Patients: An Immunohistochemical Study

2020 ◽  
Author(s):  
Dalia Rifaat Al-sharaky ◽  
Moshira Mohammed Abdelwahed ◽  
Hend Ahmad Abdou Kassem ◽  
Abdelnaby Saied Abdelnaby
Keyword(s):  
Bladder Cancer ◽  
Cyclin D1 ◽  
Bladder Carcinoma ◽  
Foxp3 Expression ◽  
Invasive Bladder Cancer ◽  
Prognostic Impact ◽  
Inverse Relation ◽  
Muscle Invasive Bladder Cancer ◽  
Muscle Invasive

Abstract BackgroundIn Egypt, Urinary bladder carcinoma is a common malignancy accounting for 14.3% of total malignancies in both sexes with 3:1 male to female ratio. It comprises 88.3% of the total urinary system tumors. To reduce bladder cancer morbidity and mortality there is an urgent need to identify novel tumor marker which are specific enough for prognosis and can serve as effective anticancer targets .Therefore the purpose of this study is to evaluate the role of TROP2, CYCLIN D1, FOXP3 and their relationship with the established clinico-pathological parameters and overall survival of bladder cancer in Egyptian patientsMethodsUsing the standard immunohistochemical technique, TROP2, CYCLIN D1 and FOXP3 expression in 80 primary bladder carcinomas and 20 specimens as non neoplastic group were assessed. The bladder carcinoma cases included 50 cases with muscle invasive bladder cancer and 30 cases with non-muscle invasive bladder cancer ResultsOverexpression of both TROP2 and FOXP3 implied poor prognostic impact as significantly associated with muscle invasive bladder cancer, high grade, advanced stage, lymph node involvement and high mitotic count. Cyclin D1 displayed an inverse relation with both TROP2 and FOXP3 reflecting a favorable prognostic impact. Tumoral FOXP3 expression is directly correlated with peritumoral FOXP3+ lymphocytes expression. TROP2, CYCLIN D1, FOXP3 expression didn’t affect the overall survival of the studied sample.ConclusionsThe inverse relation between Cyclin D1 and TROP2 proposes consumption of Cyclin D1 by TROP2 as a ligand in the urinary bladder carcinogenesis. Strong diffuse overexpression of both TROP2, and FOXP3 could be promising potential biomarkers for identifying patients with poor prognostic factors in bladder cancer serving as potential targets for cancer therapy.

Sex and Racial Disparities in the Treatment and Outcomes of Muscle-invasive Bladder Cancer

Urology ◽  
2020 ◽  
Author(s):  
Jessica Marinaro ◽  
Alexander Zeymo ◽  
Jillian Egan ◽  
Filipe Carvalho ◽  
Ross Krasnow ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Racial Disparities ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
Muscle Invasive

A prognostic immune predictor, HLA-DRA, plays diverse roles in non-muscle invasive and muscle invasive bladder cancer

2020 ◽  
Author(s):  
Xuan-Mei Piao ◽  
Ho Won Kang ◽  
Pildu Jeong ◽  
Young Joon Byun ◽  
Hee Youn Lee ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
Muscle Invasive

339: Selective Bladder Preservation by Transurethral Layer-Section in T2 Muscle-Invasive Bladder Cancer

2007 ◽  
Vol 177 (4S) ◽  
pp. 114-115
Author(s):  
Young Deuk Choi ◽  
Kang Su Cho ◽  
Soung Yong Cho ◽  
Hyun Min Choi ◽  
Nam Hoon Cho
Keyword(s):  
Bladder Cancer ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
Bladder Preservation ◽  
Muscle Invasive
Sign in / Sign up

Export Citation Format

Share Document